Plant Name: Citrus unshiu
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NMUR2; | |
| FFAR1; ADRA2C; ADRA2A; HCAR2; TAAR1; OXER1; | |
| PTPN1; | |
| GAA; ACHE; | |
| FAAH; TDP1; BLM; HPGD; ALOX12; HSD17B10; ALDH1A1; ALOX15; USP2; UBE2N; POLB; | |
| HTR3A; | |
| TRPA1; TRPV1; | |
| MAPK1; PIM1; | |
| CA2; CA12; CA1; CA9; CA3; CA5A; CA14; CA5B; CA4; CA6; CA7; | |
| PPARA; PPARD; PPARG; | |
| ESR2; | |
| RXRA; | |
| THRB; | |
| KDM4E; | |
| PTGS1; | |
| MMP9; MMP1; MMP2; | |
| TLR2; | |
| HIF1A; TP53; NFKB1; | |
| FUT7; | |
| ABCG2; | |
| LMNA; RAB9A; NPC1; FABP3; FABP5; FABP2; FABP4; MCL1; HTT; MAPT; THPO; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| 5HT3 receptor | HTR3A | Serotonin 3a (5-HT3a) receptor | P46098 | CHEMBL1899 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | UBE2N | Ubiquitin-conjugating enzyme E2 N | P61088 | CHEMBL6089 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group A | THRB | Thyroid hormone receptor beta-1 | P10828 | CHEMBL1947 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 2 group B | RXRA | Retinoid X receptor alpha | P19793 | CHEMBL2061 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Small molecule receptor (family A GPCR) | TAAR1 | Trace amine-associated receptor 1 | Q96RJ0 | CHEMBL5857 |
| Small molecule receptor (family A GPCR) | OXER1 | Oxoeicosanoid receptor 1 | Q8TDS5 | CHEMBL1628461 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.871E-13 | 4.526E-10 | BLM, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR2, MMP1, MMP2, MMP9, PPARA, PPARD, PPARG, PTPN1, RXRA, THRB, TP53 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.861E-08 | 9.881E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.294E-08 | 1.162E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 3.156E-08 | 1.527E-05 | ESR2, PPARA, PPARD, PPARG, RXRA, THRB |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.095E-08 | 1.938E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 9.866E-08 | 3.836E-05 | ESR2, PPARA, PPARD, PPARG, RXRA, THRB |
| BP | GO:0007610; behavior | GO:0007610; behavior | 1.214E-07 | 4.557E-05 | GAA, HIF1A, HTT, MAPK1, MAPT, NMUR2, NPC1, PPARA, THRB, TLR2, TP53, TRPV1, USP2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.763E-07 | 5.905E-05 | ALOX12, ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 2.220E-07 | 7.109E-05 | ALDH1A1, ALOX12, ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, GAA, HPGD, HSD17B10, KDM4E, PPARD, PPARG, PTGS1 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 4.778E-07 | 1.334E-04 | ABCG2, ACHE, ADRA2A, ADRA2C, BLM, ESR2, HPGD, HTT, MAPK1, MAPT, MCL1, MMP9, NFKB1, PPARG, RAB9A, SMN1, SMN2, TP53, TRPA1, TRPV1, USP2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 5.922E-07 | 1.554E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, PTGS1 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.071E-06 | 2.507E-04 | CYP1A2, CYP2C19, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.130E-06 | 2.564E-04 | CYP1A1, POLB, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.130E-06 | 2.564E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.362E-06 | 5.092E-04 | FABP2, FABP3, FABP4, FABP5 |
| MF | Unclassified; | GO:0004872; receptor activity | 4.254E-06 | 8.709E-04 | ADRA2A, ADRA2C, ESR2, FFAR1, HCAR2, HPGD, HTR3A, NMUR2, NPC1, OXER1, PPARA, PPARD, PPARG, RXRA, TAAR1, THRB, TLR2, TRPV1, TSHR |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 5.775E-06 | 1.103E-03 | FABP3, NMUR2, PPARA, PPARD, PPARG |
| BP | GO:0009987; cellular process | GO:0051289; protein homotetramerization | 9.434E-06 | 1.671E-03 | HSD17B10, RXRA, TP53, TRPA1, TRPV1 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.054E-05 | 1.821E-03 | ESR2, PPARA, PPARD, PPARG, RXRA, THRB |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.158E-05 | 1.940E-03 | CYP1A2, CYP2C19, CYP3A4 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.292E-05 | 2.148E-03 | ADRA2A, CA2, CA7, HCAR2, HIF1A, HTT, MAPK1, NPC1, TRPA1, TRPV1 |
| BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 1.327E-05 | 2.173E-03 | MMP2, MMP9, PPARD, RXRA |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.448E-05 | 2.301E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.448E-05 | 2.301E-03 | ALOX12, ALOX15 |
| MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 1.909E-05 | 2.969E-03 | ADRA2A, ADRA2C, HIF1A, MCL1, NFKB1, PPARD, PPARG, RXRA, TLR2, TP53 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.530E-05 | 3.853E-03 | CA2, CA7, HCAR2, HIF1A, HTT, MAPK1, NPC1 |
| BP | GO:0050896; response to stimulus | GO:0043279; response to alkaloid | 2.589E-05 | 3.916E-03 | BLM, HTR3A, PPARG, TP53, TRPV1 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.916E-05 | 4.320E-03 | ALOX12, ALOX15, HPGD |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 3.174E-05 | 4.638E-03 | ABCG2, CA12, CA2, CA7, HIF1A, HTT, MAPK1, NMUR2, TP53, TRPA1, TRPV1 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 3.422E-05 | 4.934E-03 | ESR2, PPARA, PPARD, PPARG, RXRA, THRB |
| BP | GO:0002376; immune system process | GO:0001774; microglial cell activation | 3.531E-05 | 5.026E-03 | MAPT, TLR2, TRPV1 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 3.531E-05 | 5.026E-03 | CYP1A1, PPARD, PPARG |
| BP | GO:0032502; developmental process | GO:0048513; animal organ development | 3.746E-05 | 5.262E-03 | ACHE, CA2, CYP19A1, CYP1A1, CYP1A2, HIF1A, HPGD, HTT, MAPK1, POLB, PPARA, PPARD, PPARG, RXRA, USP2 |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 3.930E-05 | 5.485E-03 | MAPK1, MAPT, PPARA, PPARG, PTPN1, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0050968; detection of chemical stimulus involved in sensory perception of pain | 4.333E-05 | 5.660E-03 | TRPA1, TRPV1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.333E-05 | 5.660E-03 | CA2, CA7 |
| BP | GO:0032501; multicellular organismal process | GO:0050955; thermoception | 4.333E-05 | 5.660E-03 | TRPA1, TRPV1 |
| MF | GO:0005215; transporter activity | GO:0097603; temperature-gated ion channel activity | 4.333E-05 | 5.660E-03 | TRPA1, TRPV1 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 4.333E-05 | 5.660E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 4.333E-05 | 5.660E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 4.333E-05 | 5.660E-03 | ADRA2A, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 4.333E-05 | 5.660E-03 | ALOX12, ALOX15 |
| MF | GO:0005488; binding | GO:0050692; DBD domain binding | 4.333E-05 | 5.660E-03 | PPARG, RXRA |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 5.397E-05 | 6.913E-03 | HIF1A, MMP1, MMP2, MMP9, TRPV1 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 5.825E-05 | 7.248E-03 | BLM, CYP1A1, CYP1B1, MAPK1, NFKB1, NPC1, PPARG, TRPV1 |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 5.901E-05 | 7.301E-03 | ALDH1A1, CYP19A1, CYP1A1, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019216; regulation of lipid metabolic process | 7.368E-05 | 8.580E-03 | ADRA2A, CYP1A1, FABP3, HCAR2, NFKB1, PPARA, PPARG, RXRA |
| BP | GO:0008152; metabolic process | GO:0070988; demethylation | 7.701E-05 | 8.779E-03 | CYP1A1, CYP1A2, CYP3A4, KDM4E |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 7.888E-05 | 8.849E-03 | HPGD, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:1902533; positive regulation of intracellular signal transduction | 7.916E-05 | 8.849E-03 | ADRA2A, ADRA2C, ALOX15, CYP1B1, HTT, MAPK1, MCL1, PPARD, PTPN1, THPO, TLR2, TP53, UBE2N |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 7.958E-05 | 8.849E-03 | CYP19A1, NFKB1, PPARA, PPARD, PPARG |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 7.914E-05 | 8.849E-03 | ADRA2A, CA2, CA4, CA9, HPGD, TSHR |
| MF | GO:0005488; binding | GO:0008134; transcription factor binding | 8.107E-05 | 8.961E-03 | HIF1A, HTT, MAPK1, NFKB1, PIM1, PPARA, PPARD, PPARG, RXRA, TP53 |
| BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 8.292E-05 | 9.119E-03 | CA3, HPGD, HTR3A, POLB, TP53 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 8.644E-05 | 9.137E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 8.644E-05 | 9.137E-03 | ADRA2A, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 8.644E-05 | 9.137E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.644E-05 | 9.137E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.046E-05 | 9.516E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0043434; response to peptide hormone | 9.373E-05 | 9.718E-03 | FABP3, NFKB1, PPARA, PPARG, TLR2, TRPV1, TSHR |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.616E-24 | 3.518E-20 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.323E-18 | 4.531E-14 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 8.493E-17 | 3.082E-13 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 9.936E-24 | 1.610E-21 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 3.730E-12 | 3.021E-10 | FABP2; FABP3; RXRA; FABP4; FABP5; MMP1; PPARG; PPARA; PPARD |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.083E-07 | 2.205E-05 | MMP1; MMP2; MAPK1; MMP9; TP53 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.966E-06 | 7.704E-05 | RXRA; MMP1; MMP2; MAPK1; PPARG; HIF1A; TP53; MMP9; NFKB1; PPARD |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.663E-06 | 7.742E-05 | ALOX15; MAPK1; ALOX12; HTR3A; CYP2C19; PTGS1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.378E-06 | 7.704E-05 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 3.823E-06 | 7.742E-05 | RXRA; MAPK1; PPARG; TP53 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.322E-05 | 2.379E-04 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.823E-06 | 7.742E-05 | CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 5.880E-05 | 8.659E-04 | PIM1; MAPK1; NFKB1; PPARD |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 7.387E-05 | 9.475E-04 | THRB; NMUR2; TRPV1; ADRA2C; TAAR1; ADRA2A; TSHR |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 5.454E-05 | 8.659E-04 | RXRA; HPGD; PPARG; TP53; MMP9; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.060E-04 | 1.073E-03 | MMP2; MAPK1; TP53; HIF1A; MMP9; TLR2 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 7.643E-05 | 9.475E-04 | RXRA; THRB; MAPK1; TP53; HIF1A |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.141E-04 | 1.087E-03 | PIM1; CYP1B1; MAPK1; TP53; MMP9; NFKB1; MCL1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 8.188E-05 | 9.475E-04 | ALOX15; ALOX12; CYP2C19; PTGS1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.710E-04 | 1.319E-03 | LMNA; MAPK1; TP53; NFKB1; MCL1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.345E-04 | 1.186E-03 | RXRA; MAPK1; PPARA; TP53; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 9.855E-05 | 1.064E-03 | CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.080E-04 | 1.531E-03 | MAPK1; TP53; MMP9; NFKB1; TLR2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.549E-04 | 1.255E-03 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 5.376E-04 | 3.483E-03 | MMP2; PIM1; MAPK1; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.391E-04 | 1.186E-03 | RXRA; CA2; CYP3A4; ABCG2 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 4.984E-04 | 3.364E-03 | MMP2; MAPK1; MMP9; ESR2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 8.566E-04 | 5.140E-03 | HCAR2; MAPK1; PPARA; NFKB1; TSHR |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.645E-03 | 8.594E-03 | RXRA; MAPK1; TP53; NFKB1; TLR2; MCL1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.870E-03 | 9.241E-03 | FUT7; GAA; CYP1A2; ALOX15; ALDH1A1; CYP1A1; ALOX12; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.629E-03 | 8.594E-03 | RAB9A; TP53; NFKB1; TLR2 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.171E-03 | 6.541E-03 | RXRA; MAPK1; TP53 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 8.411E-04 | 5.140E-03 | CYP1A1; CYP1B1; CYP19A1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.171E-03 | 6.541E-03 | FABP4; TSHR; PTGS1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.354E-04 | 3.067E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.882E-03 | 9.241E-03 | MAPK1; TP53; NFKB1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.965E-03 | 9.365E-03 | MAPK1; TP53; HIF1A |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.415E-03 | 1.043E-02 | MAPK1; NFKB1; ESR2 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.512E-03 | 1.043E-02 | MAPK1; TP53; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.138E-03 | 9.897E-03 | CYP1A2; CYP3A4; CYP2C19 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 7.053E-03 | 2.410E-02 | POLB; MAPK1; TP53; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 4.397E-03 | 1.696E-02 | MAPK1; TP53; NFKB1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 2.228E-03 | 1.003E-02 | RXRA; PPARA; NFKB1 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 5.750E-03 | 2.117E-02 | TRPA1; ALOX12; TRPV1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 2.512E-03 | 1.043E-02 | MAPK1; NFKB1; TLR2 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 5.122E-03 | 1.930E-02 | PPARG; TP53; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 3.993E-03 | 1.578E-02 | RXRA; TP53; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 6.599E-03 | 2.376E-02 | MAPK1; HIF1A; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 7.142E-03 | 2.410E-02 | MAPK1; NFKB1; TLR2 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 6.777E-03 | 2.387E-02 | MAPK1; NFKB1; TLR2 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 7.907E-03 | 2.562E-02 | MAPK1; MMP9; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 7.711E-03 | 2.549E-02 | PTPN1; PPARA; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.480E-02 | 4.360E-02 | MAPK1; MAPT; TP53; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 9.575E-03 | 3.042E-02 | MAPK1; NFKB1; TLR2 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.002E-02 | 3.063E-02 | MAPK1; TP53; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.296E-02 | 3.887E-02 | MAPK1; PPARG; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.002E-02 | 3.063E-02 | MAPK1; TP53; NFKB1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.589E-02 | 4.598E-02 | MAPK1; TP53 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 3.249E-03 | 1.316E-02 | CA2; CA4 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | TRPV1; PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; CYP3A4; FAAH |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | HTR3A; HTR3A |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR3A |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR3A |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HCAR2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PPARG |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | FAAH; PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE; ADRA2C; MAPT; PPARG; PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; FFAR1; NFKB1; PPARD; HCAR2; PPARG; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9 |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| NA: NA | Vomiting | NA | HTR3A |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | THRB |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1 |
| NA: NA | Dyslipidemia | NA | PPARD |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Local anaesthetic | R20.0 | HTR3A |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; PTGS1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; FFAR1; PPARG |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; MMP9; PTGS1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR3A; ADRA2C |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HCAR2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TRPV1; ADRA2C |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD; HCAR2 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| NA: NA | Esophagus sensitivity | NA | TRPV1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | TRPV1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | TRPV1; PTGS1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; CA1; CA9; MAPK1; MMP9; NFKB1; ACHE; TLR2; PIM1; MMP2; MCL1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; HCAR2; THRB |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | TRPV1 |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; ACHE; ADRA2C |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | TRPA1; ACHE; TRPV1; TRPV1; ADRA2C; ADRA2A; FAAH; PTGS1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; MMP2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1 |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | HTR3A; TRPV1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2 |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; TRPV1 |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; PTGS1 |
| C00-D49: Neoplasms | Cutaneous T-cell lymphoma | C84.0, C84.1 | RXRA |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; PTGS1 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH; HCAR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; PPARD; PPARD; ADRA2C; PPARG |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; CA9; MAPK1; MMP9; TLR2; MMP2 |